Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Clinical Study to Evaluate the Safety of CG-P5 Peptide Eye Drops (Self-administered and Topically Applied) in Patients Diagnosed With Age-related Wet Macular Degeneration

Next Previous
Trial Profile

Phase I Clinical Study to Evaluate the Safety of CG-P5 Peptide Eye Drops (Self-administered and Topically Applied) in Patients Diagnosed With Age-related Wet Macular Degeneration

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CG P5 (Primary) ; Aflibercept
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Caregen

Most Recent Events

  • 07 Feb 2025 Planned End Date changed from 1 Nov 2024 to 1 Aug 2025.
  • 07 Feb 2025 Planned primary completion date changed from 1 Oct 2024 to 1 May 2025.
  • 07 Feb 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top